Based on studies such as KEYNOTE-024, KEYNOTE-042, and KEYNOTE-407, the 2020 CSCO guidelines recommend pembrolumab as a single agent (PD-L1 TPS ≥ 50% only) and pembrolumab in combination with paclitaxel and platinum for the first-line treatment of advanced squamous cell carcinoma of the lung. This evidence concerns the gene CD274 and squamous cell lung carcinoma.